Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2905515 | 0.98 | TSHR (0.42) | TSHRBACE2SLC22A12HTTALDH1A1 | |
| SCHEMBL426896 | 0.84 | ABCG2 (0.44) | TSHRSLC22A12HTTALDH1A1IDO1 | |
| Hydrochloric Acid SCHEMBL425553 | 0.82 | ABCG2 (0.43) | TSHRSLC22A12HTTALDH1A1IDO1 | |
| SCHEMBL21966924 | 0.82 | TSHR (0.45) | TSHRBACE2SLC22A12HTTALDH1A1 | |
| SCHEMBL26546116 | 0.78 | ABCG2 (0.48) | TSHRBACE2SLC22A12HTTALDH1A1 | |
| SCHEMBL27483267 | 0.77 | HTT (0.46) | TSHRBACE2SLC22A12HTTALDH1A1 | |
| SCHEMBL10986676 | 0.77 | TSHR (0.41) | TSHRBACE2SLC22A12HTTALDH1A1 | |
| SCHEMBL26328301 | 0.77 | TSHR (0.41) | TSHRBACE2SLC22A12HTTALDH1A1 | |
| SCHEMBL897882 | 0.76 | GRM4 (0.47) | IDO1GAAABCG2 | |
| SCHEMBL3833327 | 0.76 | SLC22A12 (0.50) | SLC22A12IDO1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10570129-B2 | Carboline antiparasitics | ZOETIS SERVICES LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| EP-3313837-A1 | CARBOLINE ANTIPARASITICS | Zoetis Services LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016209635-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| US-8242278-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI (JP) | 2012-04-26 | — | — | US | disclosed |
| CN-101878031-A | The inhibitors of kinases that is used for the treatment of myeloproliferative disease and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2010-11-03 | — | — | CN | disclosed |
| EP-1473286-B1 | PROCESS FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI | 2009-08-27 | — | — | US | disclosed |
| US-7554000-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050096471-A1 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1473286-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | TSHR 915/4885BACE2 221/4885SLC22A12 3824/4885 |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | TSHR 915/4885BACE2 221/4885SLC22A12 3824/4885 |
| US-10570129-B2 | Carboline antiparasitics | ADRA1D, DRD1, CHRM1 | TSHR 1186/4885BACE2 1661/4885SLC22A12 2896/4885 |
| US-20050096471-A1 | Process for producing biaryl compound | PPOX, CAT, TYR | TSHR 915/4885BACE2 221/4885SLC22A12 3824/4885 |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | DRD1, ADRA1D, DRD2 | TSHR 1180/4885BACE2 1541/4885SLC22A12 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.